Patents by Inventor Steffen Zeng

Steffen Zeng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170081418
    Abstract: Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.
    Type: Application
    Filed: June 18, 2016
    Publication date: March 23, 2017
    Inventors: Elmar KRAUS, Christoph BRUECHER, Benjamin DAELKEN, Steffen ZENG, Frank OSTERROTH, Christoph UHEREK, Silke AIGNER, Matthias GERMER, Gregor SCHULZ, Thomas HAEDER
  • Patent number: 9387261
    Abstract: Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: July 12, 2016
    Assignees: BIOTEST AG, IMMUNOGEN INC.
    Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner, Matthias Germer, Gregor Schulz, Thomas Haeder
  • Publication number: 20160185854
    Abstract: Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells.
    Type: Application
    Filed: July 29, 2015
    Publication date: June 30, 2016
    Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Matthias Germer, Steffen Zeng, Frank Osterroth, Silke Aigner, Gregor Schulz, Christoph Uherek
  • Patent number: 9289509
    Abstract: Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: March 22, 2016
    Assignees: Biotest AG, Immunogen Inc.
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, Andre Engling, Thomas Haeder, Andrea Wartenberg-Demand, Gabriele Niemann, Chantal Zuber, Niklas Czeloth, Silke Aigner, Steffen Zeng, Gregor Schulz
  • Patent number: 9221914
    Abstract: Disclosed is a human murine chimeric antibody targeting CD138 which substantially retains the antigen binding region of its murine counterpart. The engineered antibody displays improved binding affinities to the antigen and/or more homogenous binding to target cells relative to its murine counterpart. A constant region of the immunoglobulin heavy chain is preferably an IgG4 isotype constant region.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: December 29, 2015
    Assignee: BIOTEST AG
    Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Matthias Germer, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner, Gregor Schulz
  • Patent number: 9011864
    Abstract: Disclosed are methods, compositions and kits for improving targeting, in particular tumor targeting, of immunoconjugates. The method and composition relies on the sequestration of non-target cells that also express the antigen the immunoconjugate targets. Sequestration of those non-target cells in a variety of ways is disclosed. The methods, compositions and kits allow appropriate sequestration of non-target cells while maintaining a high degree of effectiveness of the immunoconjugates against target cells.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: April 21, 2015
    Assignees: Biotest AG, Immunogen, Inc.
    Inventors: Gregor Schulz, Christoph Bruecher, Frank Osterroth, Steffen Zeng, Christoph Uherek, Silke Aigner, Benjamin Daelken, Markus Ruehle, Elmar Kraus
  • Publication number: 20110123554
    Abstract: Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.
    Type: Application
    Filed: May 5, 2010
    Publication date: May 26, 2011
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, Andre Engling, Thomas Haeder, Andrea Wartenberg-Demand, Gabriele Niemann, Chantal Zuber, Niklas Czeloth, Silke Aigner, Steffen Zeng
  • Publication number: 20090232810
    Abstract: Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.
    Type: Application
    Filed: December 23, 2008
    Publication date: September 17, 2009
    Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner, Matthias Germer
  • Publication number: 20090181038
    Abstract: Disclosed are methods, compositions and kits for improving targeting, in particular tumor targeting, of immunoconjugates. The method and composition relies on the sequestration of non-target cells that also express the antigen the immunoconjugate targets. Sequestration of those non-target cells in a variety of ways is disclosed. The methods, compositions and kits allow appropriate sequestration of non-target cells while maintaining a high degree of effectiveness of the immunoconjugates against target cells.
    Type: Application
    Filed: December 23, 2008
    Publication date: July 16, 2009
    Inventors: Gregor Schulz, Christoph Bruecher, Frank Osterroth, Steffen Zeng, Christoph Uherek, Silke Aigner, Benjamin Daelken, Markus Ruehle, Elmar Kraus
  • Publication number: 20090175863
    Abstract: Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells.
    Type: Application
    Filed: December 23, 2008
    Publication date: July 9, 2009
    Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Matthias Germer, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner
  • Publication number: 20050069979
    Abstract: The invention provides a method for producing a recombinant polypeptide of interest which method comprises: (a) providing a host cell which comprises a nucleotide sequence which encodes the recombinant polypeptide of interest and which directs expression of the recombinant polypeptide of interest in the host cell; (b) providing a serum-free culture medium which comprises (i) water, a plant-derived peptone, an osmolality regulator, a buffer, an energy source, at least one amino acid, a lipid source or precursor, a source of iron, non-ferrous metal ions and optionally one or more vitamins and cofactors; and (ii) does not contain any full-length polypeptides; and (c) culturing the host cell in the culture medium under conditions that allow for expression of the recombinant polypeptide of interest.
    Type: Application
    Filed: November 26, 2002
    Publication date: March 31, 2005
    Inventors: Steffen Zeng, Franz-Markus Bogner, Renate Kunert, Dethardt Mueller, Florian Unterluggauer
  • Publication number: 20020019031
    Abstract: In Chinese hamster ovary cells for producing proteins, the growth phase is uncoupled from the production phase. In a method for preparing the Chinese hamster ovary cells and with the use of the Chinese hamster ovary cells for preparing proteins, a seed culture of high cell density is prepared which cells are grown to confluence and genetic material is transferred into the cells after the formation of a confluent surface (G1 phase).
    Type: Application
    Filed: April 13, 2001
    Publication date: February 14, 2002
    Inventors: Detlef Eisenkratzer, Andre Dinter, Andre Kiesewetter, Steffen Zeng, Manfred Biselli, Eric G. Berger